Business Type | Exporter, Supplier, Retailer, Wholesaler, Trader, Distributor, Importer |
Application | Medical Use |
Country of Origin | India |
Packaging Size | 0.5 |
Click to view more |
Preferred Buyer From
Location | Worldwide |
Product Details
The approval was based on data from the phase 3b SUSTAIN FORTE trial (ClinicalTrials.gov Identifier: NCT03989232), which compared semaglutide 2mg to 1mg in adults with type 2 diabetes. Patients received 1 injection per week during the 12-week dose escalation period until the target dose of 2mg or 1mg was achieved and continued on the therapeutic dose from week 13 to week 40.“With a 2mg dose, we have an additional option so patients can stay on the same medication therapy even if their blood sugar needs shift,” said Dr Juan Pablo Frias, medical director of Velocity Clinical Research, Los Angeles and principal investigator of SUSTAIN FORTE
Hi! Simply click below and type your query.
Our experts will reply you very soon.